57,300
+5.52%
Close of 9 Nov 2026, in KRW
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Hanmi Science Co
Its shares trade on KRX under the ticker 008930.KS. It has been listed since 20 June 1988. In the fiscal year to 31 December 2025, it reported revenue of ₩1.36trn and net income of ₩118.37bn. At that date it held total assets of ₩1.49trn and shareholders' equity of ₩961.85bn.
Hanmi Science Co., Ltd. engages in the management of its subsidiaries. The company is headquartered in Hwaseong, Gyeonggi-Do. Through subsidiaries in Japan, Europe and Korea, the Company operates in three segments. The Pharmaceutical Products Wholesale segment mainly engages in the distribution of pharmaceutical products. The Holding Business segment mainly engages in the business of controlling subsidiaries. The Other segment mainly engage in the production and sales of pharmaceuticals, and the supply of quasi-drugs and health functional foods, beverages and functional cosmetics.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 20 Jun 1988
- Website
- hanmiscience.co.kr ↗
Leadership
Pay as last reported
- Mr. Jong Yun YimCo-President, Director, since 2009₩1.13bn
- Ms. Ju Hyeon YimCo-President, Director, since 2009₩1.15bn
- Mr. Jong Hun YimChief Executive Officer, Director, since 2009
- Mr. Seong Jae ShinManaging Director
- Mr. Chang Ju ChoiAssistant Managing Director
- Mr. Yin Yeong ChoiOther Non-Executive Director
- Mr. Sun Gi GwonAssistant Managing Director
- Mr. Dae Su JungAssistant Managing Director
- Mr. Seong Hun KimAssistant Managing Director
- Mr. Seung Yeop LeeAssistant Managing Director
- Mr. Jun Seop ShinAssistant Managing Director
- Mr. Wu Hyeon LeeDirector
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 5
- Environment
- 6
- Social
- 7
- Governance
- 4
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Hanmi Science Co Ltd has a strong emphasis on research and development, allowing them to continuously innovate and develop new products. This gives them a competitive advantage in the market and enables them to meet the evolving needs of their customers.
- The company offers a wide range of products in various therapeutic areas, including pharmaceuticals, vaccines, and medical devices. This diversified portfolio helps them cater to different customer segments and provides stability in their revenue streams.
- Hanmi Science Co Ltd has established a strong market presence, both domestically and internationally. Their products are well-regarded, and they have built a reputation for quality and reliability. This helps them attract and retain customers, as well as forge strategic partnerships.
Weaknesses
- While Hanmi Science Co Ltd has a robust product portfolio, they still rely heavily on a limited number of key products for a significant portion of their revenues. This makes them vulnerable to market fluctuations and increased competition in those specific product categories.
- Compared to some of their larger competitors, Hanmi Science Co Ltd has a relatively small market share. This can limit their bargaining power with suppliers and customers, as well as hinder their ability to invest in new technologies or expand their market reach.
Opportunities
- The company has an opportunity to expand its presence in emerging markets, where there is a growing demand for healthcare products. Additionally, exploring international markets further can help Hanmi Science Co Ltd tap into new customer bases, diversify their revenue streams, and reduce dependence on any one market.
- Forming strategic partnerships and collaborations with other pharmaceutical companies or research institutions can provide Hanmi Science Co Ltd with access to new technologies, resources, and markets. These alliances can accelerate their product development process and enable them to stay ahead of competitors.
Threats
- The pharmaceutical and healthcare industry is highly competitive, with numerous players vying for market share. Hanmi Science Co Ltd faces competition from both domestic and international companies, which can pose a threat to their market position and profitability.
- Operating in the pharmaceutical sector involves stringent regulations and compliance requirements. Changes in government policies, pricing regulations, or delays in product approvals can create challenges for Hanmi Science Co Ltd, impacting their ability to bring new products to the market and affecting their revenue streams.
- Rapid advancements in technology and the emergence of alternative treatment options can pose a threat to traditional pharmaceutical companies like Hanmi Science Co Ltd. They need to stay updated with the latest trends and invest in research to ensure their products remain relevant and competitive in the market.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.